Eli Lilly and Incyte’s Rheumatoid arthritis gains first approval from EU Commision
Eli Lilly’s Olumiant has achieved its first regulatory approval with a nod from the European Commission to treat moderate-to-severe active rheumatoid arthritis. The decision allows the treatment to be used either as a monotherapy or in combination with methotrexate to treat adult patients with the condition who have responded inadequately or are intolerant to one